False Reassurance: Complications of Mi2+ Dermatomyositis. by Berlin, Grace, DO et al.
Lehigh Valley Health Network
LVHN Scholarly Works
Department of Medicine
False Reassurance: Complications of Mi2+
Dermatomyositis.
Grace Berlin DO
Lehigh Valley Health Network, grace.berlin@lvhn.org
Susan Kim MD
Lehigh Valley Health Network, Susan.Kim@lvhn.org
Carolyn Casey
Lehigh Valley Health Network, Carolyn.Casey@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/medicine
Part of the Medical Sciences Commons, and the Rheumatology Commons
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Berlin, G. Kim, S. Casey, C. (2017, September 16). False Reassurance: Complications of Mi2+ Dermatomyositis. Poster Presented at:
Pennsylvania Rheumatology Society, Harrisburg, PA.
CLINICAL CASE
Berlin G, Kim SS, Casey C 
Lehigh Valley Health Network, Allentown, Pennsylvania
False Reassurance: Complications of Mi2+ Dermatomyositis
© 2017 Lehigh Valley Health Network
INTRODUCTION
References:
1.  Betterridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to 
support diagnosis of myositis. J Intern Med. 2016 Jul:280(1):8-23.  
2.  Fiorentino D, Chung L, Zwerner J, Rosen A, Casciola-Rosen L. The mucocutaneous 
and sys-temic phenotype of dermatomyositis patients with antibodies to MDA5 
(CADM-140): A retro-spective study. J Am Acad Dermatol. 2011 Jul:65(1):25-34. 
Myositis-specific autoantibodies have been beneficial for both diagnostic purposes as well as understanding 
the associated clinical phenotypes.  Anti-Mi2-antibodies are strongly associated with dermatomyositis (DM) and 
have hallmark features of cutaneous disease, milder muscle involvement, and an overall positive prognosis1.  
Identification of typical characteristics of antibody-associated myositis can be helpful for both diagnostic 
purposes as well as screening for associated conditions. 
A 53 year old male who was evaluated in the rheumatology office with increased myalgia after routine exercise, 
unintentional weight loss, skin changes, and rash over the bridge of his nose found to have abnormal capillary 
nailfold findings.  Further workup showed elevated creatine kinase (CK), aldolase, liver function studies, and 
positive anti-Mi2 antibody (tested at Arup on a standardized myositis panel), consistent with the diagnosis of 
DM.  Other contributing factors for myopathy were ruled out with thyroid screen, urine drug screen, vitamin 
D level, and viral serologies.  For completeness, the patient underwent screening for malignancy and ILD 
with computed tomography of his chest/abdomen/pelvis yielding normal results.  The patient was started on 
prednisone and methotrexate with initial notable clinical improvement.  Upon further corticosteroid dose taper 
the patient developed profound ulcerations on the dorsal aspects of his metacarpal phalangeal joints, olecranon 
processes, and helix of the right ear.  As these ulcerations are more characteristic of DM with anti-melanoma 
differentiation associated gene 5 antibodies (MDA-5) than anti-Mi2 antibodies, the patient was tested and found 
to be negative for the presence of MDA-5 antibodies.  His prednisone dose was increased and methotrexate was 
continued with subsequent improvement and resolution of these lesions. Mycophenolate mofetil was added to 
the patient’s regimen as combination therapy with methotrexate given the aggressive nature of the ulcerative 
lesions.  Clinically, the cutaneous lesions improved, and he was able to be tapered off of his steroid dosing 
without recurrence of ulcerations. 
CONCLUSION
The skin ulcerations the patient developed were atypical for anti-
Mi2 associated DM1.  Research regarding the development of 
these ulcerations correlates more with patient’s positivity for 
MDA-5 antibodies, which portends more severe disease with 
worse prognosis2.  Identification of clinical phenotype of myositis-
associated and myositis-specific autoantibodies assists in the 
diagnostic workup and management of related conditions.  Although 
management can be adjusted by the provider when the disease does 
not fit the typical phenotype, concerns truly arise with respect to 
predicting complications of potentially severe disease such as ILD or 
risk of malignancy.  This case demonstrates the clinical conundrum 
regarding screening and prognostic implications for patients who 
demonstrate worrisome features not usually associated with the 
patient’s antibody phenotype.  
Table 1. Features of Myositis-specific Autoantibodies
Myositis-specific autoantibody Typical Characteristics/Associations
Anti-Mi2+ autoantibodies
•  Cutaneous features: Gottron’s papules, helio-trope rash, V-sign and shawl sign rashes, 
cuticular overgrowth.
•  Pulmonary features: no typical pulmonary involvement.
•  Typically respond well to immunosuppressive therapy.
Anti-MDA5 autoantibodies
•  Mucocutaneous features: palmar erythema-tous macules+/-papules with higher likelihood of 
cutaneous ulceration. Gum pain, alopecia, mechanic hands, Gottron sign. 
• ILD-association, especially rapidly progres-sive lung disease.
Comment: Typical features associated with anti-Mi2+ and anti-MDA5 autoantibodies1,2.
